We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+12.16%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$306M
AUM Growth
-$97.7M
Cap. Flow
-$113M
Cap. Flow %
-36.85%
Top 10 Hldgs %
75.57%
Holding
48
New
14
Increased
7
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$12.7M
2
ALDX icon
Aldeyra Therapeutics
ALDX
+$9.84M
3
PFE icon
Pfizer
PFE
+$7.88M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.57M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.53M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$26.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$24.7M
3
NUAN
Nuance Communications, Inc.
NUAN
+$14.6M
4
JNJ icon
Johnson & Johnson
JNJ
+$13.7M
5
HUM icon
Humana
HUM
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 78.22%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BGMS
26
Bio Green Med Solution Inc
BGMS
$4.91M
$1.85M 0.61%
87
+5
+6% +$124K
FEMY icon
27
Femasys
FEMY
$8.64M
$1.53M 0.5%
+9,438
New +$1.8M
BLU
28
DELISTED
BELLUS Health Inc.
BLU
$1.17M 0.38%
375,520
-4,717
-1% -$18K
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$611K 0.2%
+96,820
New +$625K
ACRS icon
30
Aclaris Therapeutics
ACRS
$726M
– –
-164,199
Closed -$4.14M
AMRX icon
31
Amneal Pharmaceuticals
AMRX
$5.85B
– –
-139,470
Closed -$939K
BAX icon
32
Baxter International
BAX
$13.5B
– –
-314,136
Closed -$26.5M
BDTX icon
33
Black Diamond Therapeutics
BDTX
$96.8M
– –
-142,911
Closed -$3.47M
BMY icon
34
Bristol-Myers Squibb
BMY
$133B
– –
-390,992
Closed -$24.7M
CASI
35
DELISTED
CASI Pharmaceuticals
CASI
– –
-150,000
Closed -$3.6M
IMTX icon
36
Immatics
IMTX
$1.18B
– –
-121,743
Closed -$1.36M
LLY icon
37
Eli Lilly
LLY
$1.02T
– –
-48,299
Closed -$9.02M
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-180,261
Closed -$4.03M
TGTX icon
39
TG Therapeutics
TGTX
$7.96B
– –
-148,620
Closed -$7.16M
WBA
40
PUT
DELISTED
Walgreens Boots Alliance
WBA
– –
-770,000
Closed -$42.3M
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-1,210,863
Closed -$3.91M
NMTR
42
DELISTED
9 Meters Biopharma
NMTR
– –
-332,217
Closed -$7.77M
MYOV
43
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-321,101
Closed -$6.61M
AERI
44
CALL
DELISTED
Aerie Pharmaceuticals
AERI
– –
-140,000
Closed -$2.5M
AERI
45
DELISTED
Aerie Pharmaceuticals
AERI
– –
-68,472
Closed -$1.22M
AERI
46
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-140,000
Closed -$2.5M
NUAN
47
DELISTED
Nuance Communications, Inc.
NUAN
– –
-333,482
Closed -$14.6M
TRIL
48
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-578,930
Closed -$6.22M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Tri Locum Partners held 48 positions worth $306M, down 24% from $403M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Tri Locum Partners withdrew a net $113M in Q2 2021, closing 19 positions and reducing 8 holdings. Its most notable exit was Baxter International, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 72% a quarter earlier, followed by Technology.

Against the trend, Tri Locum Partners opened a new position in Cigna worth $12M.

  • Tri Locum Partners's largest Q2 2021 buy was Cigna: 50,699 shares worth $12M.
  • Tri Locum Partners added most to Regeneron Pharmaceuticals in Q2 2021, an estimated $5.53M increase.
  • Tri Locum Partners's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $13.7M.
  • Tri Locum Partners fully exited Baxter International in Q2 2021, selling an estimated $26.5M.
  • Tri Locum Partners's ten largest holdings make up 76% of its $306M portfolio in Q2 2021.
  • Tri Locum Partners opened 14 new positions and closed 19 in Q2 2021.
  • Tri Locum Partners's portfolio value fell 24% quarter-over-quarter to $306M.

Based on Tri Locum Partners's 13F filing for Q2 2021, filed 16 Aug 2021.